Instil Bio
62 hedge funds and large institutions have $45.3M invested in Instil Bio in 2023 Q2 according to their latest regulatory filings, with 13 funds opening new positions, 8 increasing their positions, 25 reducing their positions, and 24 closing their positions.
500% more call options, than puts
Call options by funds: $6K | Put options by funds: $1K
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0.39% less ownership
Funds ownership: 3.55% → 3.16% (-0.39%)
15% less funds holding
Funds holding: 73 → 62 (-11)
26% less capital invested
Capital invested by funds: $60.9M → $45.3M (-$15.6M)
46% less first-time investments, than exits
New positions opened: 13 | Existing positions closed: 24
68% less repeat investments, than reductions
Existing positions increased: 8 | Existing positions reduced: 25
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
+$322K |
| 2 |
Renaissance Technologies
New York
|
+$275K |
| 3 |
Acadian Asset Management
Boston,
Massachusetts
|
+$189K |
| 4 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
+$131K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$125K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citigroup
New York
|
-$2.46M |
| 2 |
BlackRock
New York
|
-$2.02M |
| 3 |
State Street
Boston,
Massachusetts
|
-$661K |
| 4 |
Geode Capital Management
Boston,
Massachusetts
|
-$394K |
| 5 |
JP Morgan Chase
New York
|
-$308K |
TIL Hedge Fund Activity: Q2 2023 in Review
62 of the 6,369 institutional investors tracked by Wall St. Rank reported a position in Instil Bio (TIL) for Q2 2023, worth a combined $45.3M — down 26% from $60.9M a quarter earlier.
Sellers outnumbered buyers: 24 funds closed out of TIL and 13 opened new positions — a net loss of 11 holders — while 25 trimmed existing stakes and 8 added.
The largest buyer was Millennium Management, adding an estimated $322K. The largest seller was Citigroup, cutting an estimated $2.46M.
- 62 institutional investors held Instil Bio (TIL) as of Q2 2023, down from 73 in Q1 2023.
- Funds reported $45.3M of Instil Bio stock for Q2 2023, down 26% quarter-over-quarter.
- 13 funds opened new Instil Bio positions in Q2 2023 and 24 closed out, a net change of -11 holders.
- The largest Instil Bio buyer in Q2 2023 was Millennium Management, an estimated $322K added.
- The largest Instil Bio seller in Q2 2023 was Citigroup, an estimated $2.46M sold.
Based on aggregated 13F filings for Q2 2023.